Compositions and methods for improving bone mass through modulation of receptors of PTH and fragments thereof
The present invention relates to the discovery of novel receptors for the signaling of PTH and/or fragments of PTH, and the role of cPTH in bone development. The novel PTH receptors identified are selected from the group consisting of LRP5/6, TGFβRII, BMPRII (long form and short form), ActRIIA, and ActRIIB. Specifically, the present invention provides a novel screening tool for identifying compounds that improve bone mass by affecting certain pathways that promote or downregulate bone-forming activity. This promotion of bone-forming activity could provide for treatments for bone-loss or bone density disorders and/or kidney disease. The invention further encompasses the compounds, PTH ligands, and fragments of PTH ligands described herein; pharmaceutical compositions comprising the compounds, PTH ligands, or fragments of PTH ligand; and methods of increasing bone density using the compounds, PTH ligands, or fragments of PTH ligands.
1. A method of identifying a compound, a parathyroid hormone (PTH) ligand, or a fragment of a PTH ligand that improves bone mass, comprising:
a) contacting an in vitro cell expressing a PTH receptor with a test compound, a PTH ligand, or a fragment of a PTH ligand, wherein the PTH receptor is selected from the group consisting of low density lipoprotein related protein (LRP) 5/6, transforming growth factor beta receptor, type II (TGFβRII), bone morphogenic protein receptor, type II (BMPRII), activin A receptor, type IIA (ActRII), and activin A receptor, type IIB (ActRIIB); and
b) determining whether an increase in binding between the PTH receptor and parathyroid hormone 1 receptor (PTH1R) occurs in the cell contacted with the compound, the PTH ligand, or the fragment of a PTH ligand, as compared to a control, said increase being an indication that the compound, PTH ligand, or fragment of PTH ligand improves bone mass.
2. The method of claim 1 , wherein the PTH receptor is LRP5/6.
3. The method of claim 1 , wherein the PTH receptor is TGFβRII.
4. The method of claim 1 , wherein the PTH receptor is BMPRII short form, BMPRII long form, ActRII, or ActRIIB.
5. A method of identifying a compound, a parathyroid hormone (PTH) ligand, or a fragment of a PTH ligand that enhances the interaction of parathyroid hormone 1 receptor (PTH1R) with a PTH receptor, comprising:
a) contacting an in vitro cell expressing a PTH receptor with a test compound, a PTH ligand, or a fragment of a PTH ligand, wherein the PTH receptor is selected from the group consisting of transforming growth factor beta receptor, type II (TGFβRII), bone morphogenic protein receptor, type II (BMPRII), activin A receptor, type IIA (ActRII), activin A receptor, type IIB (ActRIIB), and low density lipoprotein related protein (LRP) 5/6; and
b) determining whether binding of PTH1R with the PTH receptor is increased in the presence of the test compound, the PTH ligand, or the fragment of a PTH ligand, as compared to a control, an increase in said binding being an indication that the test compound, the PTH ligand, or the fragment of a PTH ligand enhances the interaction of PTH1R with the PTH receptor.
6. The method of claim 5 , wherein the PTH receptor is LRP5/6.
7. The method of claim 5 , wherein the PTH receptor is TGFβRII.
8. The method of claim 5 , wherein the PTH receptor is BMPRII short form, BMPRII long form, ActRII, or ActRIIB.